Fostering Further Collaboration between PMDA and Applicants with Efficient “Project Management” in Drug Development

Kazuishi Sekino
Review Director
Office of New Drug I
Pharmaceuticals & Medical Devices Agency
Disclaimer

The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to DIA, its directors, officers, employees, volunteers, members, chapters, councils, Communities or affiliates, or any organization with which the presenter is employed or affiliated.

These PowerPoint slides are the intellectual property of the individual presenter and are protected under the copyright laws of the United States of America and other countries. Used by permission. All rights reserved. DIA and the DIA logo are registered trademarks or trademarks of Drug Information Association Inc. All other trademarks are the property of their respective owners.
Outline of Presentation

1. Current Situation of Approval Review
2. The Elements of Project and Priority
3. Progress Management of Approval Review Process
4. Progress Management of Scientific Advice process
Review Time for New Drugs (median)

(Total review time = Regulatory review time + Applicant’s time)

The PMDA’s Second Mid-term Plan

The PMDA’s Third Mid-term Plan

Number of approved products

{\( \text{Total review time} = \text{Regulatory review time} + \text{Applicant’s time} \)}

PMDA: Pharmaceuticals and Medical Devices Agency

Six regulatory Authorities’ Approval Time of New Drugs in 2004-2013
The PMDA’s Third Mid-term Plan (FY2014 to FY2018)

The plan for prompt realization of “zero” review lag for new drugs

- Review Time for New Drugs (Priority Review)
  Total review time (Regulatory review time + Applicant’s time); **9 months** (6 months + 3 months)

- Review Time for New Drugs (Standard Review)
  Total review time (Regulatory review time + Applicant’s time); **12 months** (9 months + 3 months)

<table>
<thead>
<tr>
<th></th>
<th>FY2014</th>
<th>FY2015</th>
<th>FY2016</th>
<th>FY2017</th>
<th>FY2018</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Target percentile</strong></td>
<td>60%</td>
<td>60%</td>
<td>70%</td>
<td>70%</td>
<td>80%</td>
</tr>
</tbody>
</table>

PMDA: Pharmaceuticals and Medical Devices Agency

Outline of Presentation

1. Current Situation of Approval Review
2. The Elements of Project and Priority
3. Project Management for Process of Approval Review
4. Project Management for Process of Scientific Advice
The Three Elements of Project and Priority

- **Time** (start and end time, the necessary time)
- **Resource** (reviewers)
- **Scope, Quality** (different each time)

<table>
<thead>
<tr>
<th></th>
<th>Time</th>
<th>Resource</th>
<th>Scope, Quality</th>
</tr>
</thead>
<tbody>
<tr>
<td>Top Priority</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Mandatory Goal)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Second Priority</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Goal to Strive)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Allowance</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
1. Current Situation of Approval Review

2. The Elements of Project and Priority

3. Project Management for Process of Approval Review

4. Project Management for Process of Scientific Advice
Flow of Review for New Drugs (in the past)

MHLW: Ministry of Health, Labour and Welfare
NDA: New Drug Application
PMDA: Pharmaceuticals and Medical Devices Agency
PAFSC: Pharmaceutical Affairs and Food Safety Council

Standard Review: Total 12 months
Priority Review: Total 9 months

<Administrative Notice of MHLW, March 30, 2012>
厚生労働省医薬食品局審査管理課長
(公印省略)

新薬の承認の予見性向上等に向けた承認申請の取扱い及び総審査期間の考え方について

医薬品の総審査期間については、これまで行政側、申請者側双方の努力により短縮を図ってきたところであるが、これに加え、承認の予見性の向上を図る観点から、「医薬品の承認申請について」（平成17年3月31日付け薬食発第0331015号厚生労働省医薬食品局報告通知日）の別表2（１）医療用薬品の（1）から（7）まで、（9）及び（9の2）に該当する医薬品（以下この通知において「新薬品」という。）については、独立行政法人医薬品医療機器総合機構等計画（平成26年3月31日厚生労働省発第0331第44号認可）において、別添のとおり新薬の総審査期間について、平成26年度より段階的にパーセントスタイル値を上げ、平成30年度までに80パーセントを優先薬品目50ヶ、通常薬品目30ヶに達成することを目指すとしている。

今般、下記のとおり新薬品の承認の予見性向上及び、引き続き行政側と申請者側の両者が協調しながら取り組むことが重要であると感じ。医薬品の承認の取扱い及び総審査期間の考え方について定めたので、貴省関係業者に対して周知願いたい。
Flow of Review for New Drugs (at present)

<table>
<thead>
<tr>
<th>Stage</th>
<th>Standard Review</th>
<th>Priority Review</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-Submission Meeting</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NDA Filling</td>
<td>2.4 months</td>
<td>1.9 months</td>
</tr>
<tr>
<td>PMDA’s Evaluation</td>
<td>0.6 months</td>
<td>0.3 months</td>
</tr>
<tr>
<td>Initial Meeting</td>
<td>5.7 months</td>
<td>4.4 months</td>
</tr>
<tr>
<td>PMDA’s Evaluation</td>
<td></td>
<td>1.3 months</td>
</tr>
<tr>
<td>List of Questions to Applicant</td>
<td></td>
<td>1.5 months</td>
</tr>
<tr>
<td>PMDA’s Evaluation</td>
<td></td>
<td>0.9 months</td>
</tr>
<tr>
<td>External Expert Discussion</td>
<td></td>
<td>0.8 months</td>
</tr>
<tr>
<td>PMDA’s Opinion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Approval by MHLW</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PAFSC</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<Administrative Notice of MHLW, January 30, 2015>

MHLW: Ministry of Health, Labour and Welfare
NDA: New Drug Application
PMDA: Pharmaceuticals and Medical Devices Agency
PAFSC: Pharmaceutical Affairs and Food Safety Council

© 2015 DIA, Inc. All rights reserved. 12th Annual Meeting DIA JAPAN 2015 | November 15-17 | Tokyo Big Sight | Ariake
Outline of Presentation

1. Current Situation of Approval Review
2. The Elements of Project and Priority
3. Project Management for Process of Approval Review
4. Project Management for Process of Scientific Advice
**Flow of Scientific Advice for New Drug Development**

**Applicant’s Action**
- **Intention to Apply**
  - Pre-Submission Meeting
  - Scheduling
  - Preparing Document
  - PMDA’s Evaluation
  - List of Questions to Applicant
  - PMDA’s Evaluation
  - PMDA’s Opinion to Applicant
  - Face to Face Meeting

**PMDA’s Action**
- **P**harmaceuticals and **M**edical **D**evices **A**gency

**Phases and Timeframes**
- 1 week
- (2-5 weeks)
- (1 week)
- 1 week
- (1 week)
- 1 week
- 1 month

- **5 weeks**
- **2 months (8-11 weeks)**

**Minutes**
Number of Scientific Advice for New Drugs
(Review Category 1; Gastrointestinal Drugs etc.)

(N)

<https://www.pmda.go.jp/0017.html>
Example of the GANNT chart (I)

【Hypothetical situation】

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Q</td>
<td>1Q</td>
<td>2Q</td>
<td>3Q</td>
<td>4Q</td>
<td>1Q</td>
<td>2Q</td>
<td>3Q</td>
</tr>
</tbody>
</table>

**Global Phase III trial**

**Delay of enrollment of Japanese patients?**

**Top-Line Results**

**Scientific Advice**

**Applicant’s Decision Making**

**Best timing?**

**Reflection of PMDA’s opinion to protocol?**

**PMDA**

**FDA, EMA**

**US & EU**

**Japan**

**EMA:** European Medicines Agency

**FDA:** US Food and Drug Administration

**PMDA:** Pharmaceuticals and Medical Devices Agency
Example of the GANNT chart (II)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Q1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Q2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Q3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Q4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

【Hypothetical situation】

Best timing?

Reflection of PMDA’s opinion to protocol?

Best road map?

Global Phase II trial

Global Phase III trial

FDA, EMA, PMDA

PMDA

Phase I trial

Phase IIa trial

FDA, EMA

EMA: European Medicines Agency
FDA: US Food and Drug Administration
PMDA: Pharmaceuticals and Medical Devices Agency
Examples of items for the project management

- *The target product profile*
- *The strategic development plan (and current status)*
- *The GANNT chart (development history and project scheduling, including discussion to regulatory agencies)*
etc.

- Effective utilization of pre-submission meeting (sharing the information between applicant and PMDA)

**PMDA:** Pharmaceuticals and Medical Devices Agency
Thank you for your attention.

Welfare of patients!

E-mail: sekino-kazuishi@pmda.go.jp